Navigation Links
Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/13/2008

2,254 7,408

Commitments

Stockholders' equity:

Preferred stock, $0.00004 par value;

10,000 shares authorized; no shares issued

and outstanding - -

Common stock, $0.00004 par value; 150,000

shares authorized; 40,778 and 31,419 shares

issued and outstanding at December 31,

2007 and December 31, 2006, respectively 2 1

Additional paid-in capital 184,014 163,482

Stock subscription receivables - (27)

Accumulated other comprehensive income 5,895 5,869

Accumulated deficit (164,933) (144,807)

Total stockholders equity 24,978 24,518

Total liabilities and stockholders' equity $56,252 $51,172

Micromet, Inc.

Condensed Consolidated Statements of Operations

(In thousands, except per share amounts)

Three Months Ended Year Ended

December 31, December 31,

2007 2006 2007 2006

Revenues

Collaboration agreements $6,751 $12,596 $17,366 $25,449

License fees and other 234 1,211 1,018 2,134

Total revenues 6,985 13,807 18,384 27,583

Operating expenses

Research and development 9,471 7,385 29,191 28,252

In-process research and

development - - - 20,890

General and administrative 3,590 3,495 14,430 12,012

Total operating expenses 13,061 10,880 43,621
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
4. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Helix BioPharma reports Q2 2008 highlights, financial results
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
9. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
10. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
11. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... ... Costello served as Lead Levee Design Engineering Manager for a feasibility study of ... future storm surge flooding, such as occurred in Hurricane Ike in 2008. , ... protection, Costello also balanced socio-economic and environmental needs and concerns. The team ...
(Date:7/28/2015)... A n ew UK ... and commercialising innovative medicines to transform patient quality of life ... management team; blue chip investor ... Group Ltd ("Mereo"), a recently-formed speciality biopharmaceutical company, announces that ... from blue chip institutional investors and simultaneously acquired a portfolio ...
(Date:7/28/2015)... , July 28, 2015 People with a ... aids achieved significant and sometimes profound improvements in their ... devices, according to a new multicenter study led by ... the study, described online ahead of print in the journal ... and private clinics in the United States ...
(Date:7/28/2015)... July 21, 2015 Research and Markets ... the "Biomedical Refrigerators and Freezers Market - ... Forecast 2014 - 2022" report to their ... and freezers market has been segmented based on ... banks, and others. The others segment includes applications ...
Breaking Biology Technology:Preventing Storm Surge Flooding in Houston 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 3Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 2Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 3
... a day. So several speakers at the Fusion 2007 CEO-CIO ... point that "work smarter, not harder" is more than just ... of Wisconsin-Madison School of Business, summed it up: "When productivity ... him, producing more by working more hours and giving up ...
... For years I had been focusing on the wrong currency. ... I should have been looking at what they were getting ... Best Buy. , ,It's about time. A large corporation ... vested interest in flexible working (such as those selling IT ...
... the technology associated with his digital product isn't perfect, ... and transform it for the voice-recognition market. , ,Hager, ... , has ambitious plans for his Web-based, voice transcription ... plus self-correction and the ability to work with multiple ...
Cached Biology Technology:Fusion 2007: Innovation drives productivity in post 24x7 world 2How Best Buy said bye to burnout, hello to results 2How Best Buy said bye to burnout, hello to results 3How Best Buy said bye to burnout, hello to results 4How Best Buy said bye to burnout, hello to results 5Tech upstart VoVision could disrupt the voice-recognition market 2Tech upstart VoVision could disrupt the voice-recognition market 3Tech upstart VoVision could disrupt the voice-recognition market 4
(Date:7/9/2015)... JOSE, Calif. , July 9, 2015  Synaptics ... interface solutions, announced today that it will report financial ... on Thursday, July 30, 2015 after the close of ... for analysts and investors at 2:00 p.m. PT (5:00 ...   To participate on the live call, ...
(Date:7/9/2015)... , July 9, 2015  Synaptics ... developer of human interface solutions, today announced ... industry,s first fully hardware encapsulated fingerprint sensor ... authentication technology is literally off the grid, ... biometric matching within the fingerprint sensor to ...
(Date:7/8/2015)... 8, 2015  Trovagene, Inc. (NASDAQ: TROV ... announced the launch of a study that aims ... Monitoring℠ (PCM) technology for predicting response to treatment ... combination of the novel immunotherapy agents Yervoy® (ipilumumab), ... inhibitor. The 50-patient study will be led by ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... familiarity does not affect the stickleback,s ability to recognize ... thus seems to be the overruling mechanism when it ... Numerous species, from microbes to humans and even ... their kind. However, it has proven remarkably difficult to ...
... that routine screening using a non-invasive test that analyzes ... detect Down,s syndrome and other genetic fetal abnormalities in ... in Obstetrics & Gynecology , the results suggest that ... and could reshape standards in prenatal testing. ...
... PAUL) June 6, 2013 A research team led by ... Jakub Tolar, M.D., Ph.D. from the Masonic Cancer Center, University ... genetic defects in the skin cells of patients with the ... the journal Molecular Therapy and highlighted in the ...
Cached Biology News:Oh brother, where art thou? 2Non-invasive first trimester blood test reliably detects Down's syndrome 2U of M researchers find novel gene correction model for epidermolysis bullosa 2
... omental preadipocytes are isolated ... healthy donors. There is ... cells. Please inquire for ... also available. Academic discounts ...
ASCIZ...
11-keto Testosterone EIA Antiserum hormones steroids antisera antiserum eias enzyme immunoassays reagents 11-keto-testosterone...
...
Biology Products: